Format

Send to

Choose Destination
Asian J Androl. 2019 Apr 19. doi: 10.4103/aja.aja_16_19. [Epub ahead of print]

Comparison of diagnostic efficacy between transrectal and transperineal prostate biopsy: A propensity score-matched study.

Author information

1
Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
2
Department of Urology, West China Hospital, Sichuan University, West China School of Medicine, Chengdu 610041, China.
3
Department of Urology, Shanghai General Hospital Affiliated to Nanjing Medical University, Shanghai 200080, China.

Abstract

This study compared the diagnostic efficacy of transrectal ultrasound (TRUS)-guided prostate biopsy (TRBx) and transperineal prostate biopsy (TPBx) in patients with suspected prostate cancer (PCa). We enrolled 2962 men who underwent transrectal (n = 1216) or transperineal (n = 1746) systematic 12-core prostate biopsy. Clinical data including age, prostate-specific antigen (PSA) level, and prostate volume (PV) were recorded. To minimize confounding, we performed propensity score-matching analysis. We measured and compared PCa detection rates between TRBx and TPBx, which were stratified by clinical characteristics and Gleason scores. The effects of clinical characteristics on PCa detection rate were assessed by logistic regression. For all patients, TPBx detected a higher proportion of clinically significant PCa (P < 0.001). Logistic regression analyses illustrated that PV had a smaller impact on PCa detection rate of TPBx compared with TRBx. Propensity score-matching analysis showed that the detection rates in TRBx were higher than those in TPBx for patients aged >- 80 years (80.4% vs 56.5%, P = 0.004) and with PSA level 20.1-100.0 ng ml-1 (80.8% vs 69.1%, P = 0.040). In conclusion, TPBx was associated with a higher detection rate of clinically significant PCa than TRBx was; however, because of the high detection rate at certain ages and PSA levels, biopsy approaches should be optimized according to patents' clinical characteristics.

KEYWORDS:

Gleason score; biopsy; demography; propensity score; prostatic neoplasms

PMID:
31006712
DOI:
10.4103/aja.aja_16_19

Supplemental Content

Loading ...
Support Center